Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATOS Atossa Genetics

Closed Good Friday 04-17 16:00:00 EDT

0.6231

+0.0181

+2.99%

盘后0.6225

-0.0006-0.10%

19:56 EDT

High0.6300	Low0.5914	Vol415.17K
Open0.6000	D1 Closing0.6050	Amplitude6.38%
Mkt Cap80.49M	Tradable Cap80.45M	Total Shares129.17M
T/O253.56K	T/O Rate0.32%	Tradable Shares129.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ATOS","market":"US","secType":"STK","nameCN":"Atossa Genetics","latestPrice":0.6231,"timestamp":1744920000000,"preClose":0.605,"halted":0,"volume":415170,"hourTrading":{"tag":"盘后","latestPrice":0.6225,"preClose":0.6231,"latestTime":"19:56 EDT","volume":3775,"amount":2353.4768,"timestamp":1744934217366},"delay":0,"floatShares":129109733,"shares":129170004,"eps":-0.202639,"marketStatus":"Closed Good Friday","change":0.0181,"latestTime":"04-17 16:00:00 EDT","open":0.6,"high":0.63,"low":0.5914,"amount":253555.52859,"amplitude":0.063802,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.202639,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1352350800000,"exchange":"NASDAQ","adjPreClose":0.605,"preHourTrading":{"tag":"盘前","latestPrice":0.595,"preClose":0.605,"latestTime":"09:26 EDT","volume":42,"amount":25.21510152,"timestamp":1744896409928},"postHourTrading":{"tag":"盘后","latestPrice":0.6225,"preClose":0.6231,"latestTime":"19:56 EDT","volume":3775,"amount":2353.4768,"timestamp":1744934217366},"volumeRatio":0.6767208761451989,"impliedVol":1.0156,"impliedVolPercentile":0.6175},"requestUrl":"/m/hq/s/ATOS","defaultTab":"news","newsList":[{"id":"2526456528","title":"Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526456528","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526456528?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:00","pubTimestamp":1744286400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from \"Idea to IND\" , ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. . The collaboration leverages Nona's proprietary H2L2 Harbour Mice platform to identify next-generation therapeutic candidatesfor breast cancer.Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing a total solution from \"Idea to IND\" ,ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Miceplatforms","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nona-biosciences-atossa-therapeutics-partner-120000938.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nona-biosciences-atossa-therapeutics-partner-120000938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU1668664300.SGD","LU1861217088.USD","LU1861220207.SGD","DFS","BK4166","LU0106831901.USD","LU2360107671.USD","ATOS","BK4007","LENZ","LU1791807156.HKD","BK4139","BK4585"],"gpt_icon":0},{"id":"2525076017","title":"BRIEF-Atossa Therapeutics says Intas Pharmaceuticals Filed Petition For Post Grant Review Against Co- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2525076017","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525076017?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 04:24","pubTimestamp":1744057449,"startTime":"0","endTime":"0","summary":"BRIEF-Atossa Therapeutics says Intas Pharmaceuticals Filed Petition For Post Grant Review Against Co- SEC FilingApril 7  - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS INC - INTAS PHARMACEUTICALS FILES PETITION FOR POST GRANT REVIEW AGAINST CO- SEC FILINGATOSSA THERAPEUTICS INC - INTAS PHARMACEUTICALS FILES PETITION FOR INTER PARTES REVIEW AGAINST COATOSSA THERAPEUTICS INC - TO CONTEST PGR AND IPR PETITIONS - SEC FILINGSource text: [ID:n0000950170-25-051575]Further company coverage: ATOS.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL1N6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2525761110","title":"Atossa Therapeutics Inc - Intas Pharmaceuticals Files Petition for Post Grant Review Against Co- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2525761110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525761110?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 04:18","pubTimestamp":1744057107,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL1N6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2525076114","title":"Atossa Therapeutics Inc - to Contest Pgr and Ipr Petitions - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2525076114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525076114?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 04:18","pubTimestamp":1744057107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL1N6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2524125605","title":"Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2524125605","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524125605?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:59","pubTimestamp":1743508740,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atos/atossa-therapeutics/news/heres-why-were-not-too-worried-about-atossa-therapeutics-nas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","BK4139","PSQ","MNQmain","LU2095319765.USD","TQQQ","NDAQ","SQQQ","QLD","BK4585","LU2210149790.SGD","TSYW.SI","ATOS","BK4588","IE00BGHQF748.EUR","LU2210150020.SGD","USJW.SI","IE00BKPKM429.USD","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","NQmain","USAW.SI",".IXIC","QID","NVIW.SI"],"gpt_icon":1},{"id":"2523500685","title":"All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2523500685","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523500685?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 00:00","pubTimestamp":1743177609,"startTime":"0","endTime":"0","summary":"Atossa Genetics Inc.  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Atossa Genetics basically reflects positivity about its earnings outlook that could translate into buying pressure and an inc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/know-atossa-genetics-atos-rating-160009415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATOS"],"gpt_icon":0},{"id":"2522074434","title":"Atossa Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522074434","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522074434?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 21:32","pubTimestamp":1742909549,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryAtossa Therapeutics Inc ATOS.OQ reported a quarterly adjusted loss of 5 cents per share for the quarter ende","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL5N3Q816C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS"],"gpt_icon":0},{"id":"2522223560","title":"Press Release: Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522223560","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522223560?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"Ended 2024 with $71.1 million of cash and cash equivalents and no debt. Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time. SEATTLE, March 25, 2025  -- Atossa Therapeutics, Inc.  , a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments.plans to advance its lead program, -endoxifen, to target metastatic. breast cancer. The Company believes this approach may offer a more. streamlined regulatory pathway to deliver -endoxifen to patients with. urgent unmet medical needs, as the current treatment options for. metastatic breast cancer often provides limited durability of response. and substantial side effects. -endoxifen--a potent and well-tolerated. in previous clinical trials, which Atossa believes supports its potential. to fill this critical gap in treatment. Atossa also inten","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4079","BK4551","BK4218","BK4548","Z","BK4181","BK4585","BK4588","BK4139","PK","ATOS","LENZ"],"gpt_icon":0},{"id":"2521286014","title":"Atossa Therapeutics Inc  expected to post a loss of 6 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521286014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521286014?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 20:57","pubTimestamp":1742561825,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc  expected to post a loss of6cents a share - Earnings Preview Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected to show no change in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q414E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS"],"gpt_icon":0},{"id":"2520134451","title":"Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520134451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520134451?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 21:13","pubTimestamp":1742476390,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUASQTZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2518712740","title":"BRIEF-Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses","url":"https://stock-news.laohu8.com/highlight/detail?id=2518712740","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518712740?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 22:04","pubTimestamp":1741701897,"startTime":"0","endTime":"0","summary":"BRIEF-Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other usesMarch 11 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS ANNOUNCES PLANS TO ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU0R9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2518745265","title":"Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen","url":"https://stock-news.laohu8.com/highlight/detail?id=2518745265","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518745265?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 20:25","pubTimestamp":1741695936,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics (ATOS) announced its strategic decision to pursue a metastatic breast cancer indication for (Z)-endoxifen. Atossa believes that...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atossa-therapeutics-to-pursue-metastatic-breast-cancer-for-z-endoxifen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atossa-therapeutics-to-pursue-metastatic-breast-cancer-for-z-endoxifen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4079","BK4551","BK4139","BK4585","Z","LENZ","BK4588","BK4548","ATOS"],"gpt_icon":0},{"id":"2509628335","title":"Press Release: Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2509628335","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509628335?lang=en_us&edition=full_marsco","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care. SEATTLE, Feb. 05, 2025  -- Atossa Therapeutics, Inc.  , a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Cornell Medicine team for being awarded a five-year, $2.3 million grant from the Centers for Disease Control and Prevention . This grant will fund initiatives aimed at improving equitable access to care, quality of life, and survival outcomes for young breast cancer patients across New York City.Dr. Cigler, who serves as co-principal investigator for the initiative, will work alongside Dr. Vered Stearns and a multidisciplinary team at Weill Cornell Medicine to address the unique needs of young breast cancer patients, part","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4079","CDC","Z","ATOS","BK4139","LENZ","BK4585","BK4551","BK4548"],"gpt_icon":0},{"id":"2507676180","title":"Atossa Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2507676180","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507676180?lang=en_us&edition=full_marsco","pubTime":"2025-01-31 01:31","pubTimestamp":1738258260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2025 12:31 ET (17:31 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","LENZ"],"gpt_icon":0},{"id":"2507629754","title":"Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen","url":"https://stock-news.laohu8.com/highlight/detail?id=2507629754","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507629754?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 22:38","pubTimestamp":1738247937,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics  said Thursday it will not appeal a US Patent Trial and Appeal Board decision that invalidated claims in one of its patents but will continue pursuing new patent protections for its clinical-stage formulations.In August 2023, Atossa said Intas Pharmaceuticals had filed a Post Grant Review application for Atosaa's patent covering methods for making and using endoxifen.The company said Thursday that the PTAB ruled that all challenged claims in US Patent No. 11,572,334 were unpatentable, adding that the decision does not affect its current clinical formulations and that it plans to file a continuation patent application.Atossa also said it was granted a new patent covering sustained-release compositions of endoxifen.Atossa shares were 9% lower in early trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","ATOS"],"gpt_icon":0},{"id":"2507628447","title":"Atossa Therapeutics - Will Not Be Pursuing an Appeal From Ptab Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2507628447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507628447?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 21:17","pubTimestamp":1738243053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nFWN3OQ0M6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2507628423","title":"Atossa Therapeutics - Responds to Ptab Ruling on U.S. Patent No. 11,572,334 and Announces Issuance of U.S. Patent No. 12,201,591","url":"https://stock-news.laohu8.com/highlight/detail?id=2507628423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507628423?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 21:17","pubTimestamp":1738243053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nFWN3OQ0M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2507284426","title":"Atossa Therapeutics - Decision Has No Impact on Formulations Currently in Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2507284426","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507284426?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 21:17","pubTimestamp":1738243053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nFWN3OQ0M6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"gpt_icon":0},{"id":"2505018141","title":"Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505018141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505018141?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 21:15","pubTimestamp":1737638100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUAC6BLQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"gpt_icon":0},{"id":"2505018774","title":"Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505018774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505018774?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 21:15","pubTimestamp":1737638100,"startTime":"0","endTime":"0","summary":"SEATTLE, Jan. 23, 2025  -- Atossa Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company’s clinical programs and recent events. The full text of the letter follows:. As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment. Last year was vital for Atossa as we continued to demonstrate the broad utility of -endoxifen as an innovative therapy that has the potential to transform the breast cancer treatment landscape.Completion of the KARISMA-Endoxifen Phase 2 Study - One of the most significant milestones this year was the completion and announcement of results from our phase 2 KARISMA-Endoxifen Study. This study evaluated the ability of low doses o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atossa-therapeutics-issues-letter-shareholders-131500934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BN0W2W23.USD","ATOS","BK4548","FTV","Z","IE00BN0W2V16.EUR","BK4585","LU1496350502.SGD","LENZ","LU1496350171.SGD","BK4551","E","BK4161","BK4135","BK4588","IE00BN0W2T93.GBP","PK","BK4139","BK4543","BK4181","BK4201","OFS","BK4079","BK4218"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atossatherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0566},{"period":"1month","weight":-0.1404},{"period":"3month","weight":-0.2454},{"period":"6month","weight":-0.5703},{"period":"1year","weight":-0.5384},{"period":"ytd","weight":-0.34}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.293861},{"month":2,"riseRate":0.538462,"avgChangeRate":0.099322},{"month":3,"riseRate":0.384615,"avgChangeRate":0.084638},{"month":4,"riseRate":0.230769,"avgChangeRate":-0.074553},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.004454},{"month":6,"riseRate":0.583333,"avgChangeRate":0.133936},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.118738},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.056265},{"month":9,"riseRate":0.25,"avgChangeRate":-0.036311},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.201299},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.048676},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.116498}],"exchange":"NASDAQ","name":"Atossa Genetics","nameEN":"Atossa Genetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atossa Genetics,ATOS,Atossa Genetics股票,Atossa Genetics股票老虎,Atossa Genetics股票老虎国际,Atossa Genetics行情,Atossa Genetics股票行情,Atossa Genetics股价,Atossa Genetics股市,Atossa Genetics股票价格,Atossa Genetics股票交易,Atossa Genetics股票购买,Atossa Genetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction